Vendor, Plainsboro, NJ, part of Novo Nordisk Fonden
Novo Nordisk Inc.
UEI W72BJMJYBMN3, CAGE 60554
5 awards and $0 obligated between January 3, 2024 and August 24, 2026, 100% under full and open competition, against 400.4 offers on average where reported.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 5 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 36E79720D0018April 9, 2024, Full and Open Competition, 1 offers | Nac PharmaceuticalsDepartment of Veterans Affairs | Implement Cost Recovery Fee (Crf) Changes Mod.NAICS 325412, PSC 6505 | $0 |
| 36E79720D0071February 27, 2024, Full and Open Competition, 2 offers | Nac PharmaceuticalsDepartment of Veterans Affairs | This Modification Is Issued to Incorporate Novo Nordisk'S 2024 Subcontracting Plan Effective for the Period of January 1, 2024 - December 31NAICS 325412, PSC 6505 | $0 |
| 36E79725A0025August 1, 2025, Full and Open Competition, 1 offers | Nac PharmaceuticalsDepartment of Veterans Affairs | BPA for RivflozaNAICS 325412, PSC 6505 | $0 |
| 36F79719D0181January 3, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | FSSNAICS 325412, PSC 6505 | $0 |
| 36F79721D0044February 9, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | FSSNAICS 325412, PSC 6505 | $0 |
- Product and service codes
- 6505 Drugs and Biologicals
- Transactions
- 85 across 5 awards